Identification | |||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Name | Sodium bicarbonate | ||||||||||||||||||||||||
Accession Number | DB01390 | ||||||||||||||||||||||||
Type | small molecule | ||||||||||||||||||||||||
Description | Sodium bicarbonate is a white, crystalline powder that is commonly used as a pH buffering agent, an electrolyte replenisher, systemic alkalizer and in topical cleansing solutions. | ||||||||||||||||||||||||
Structure |
|
||||||||||||||||||||||||
Categories (*) | |||||||||||||||||||||||||
Molecular Weight | 84.0066 | ||||||||||||||||||||||||
Groups | approved | ||||||||||||||||||||||||
Monoisotopic Weight | 83.982338573 | ||||||||||||||||||||||||
Pharmacology | |||||||||||||||||||||||||
Indication | Sodium bicarbonate is used for the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturateprotein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of blood pigments. | ||||||||||||||||||||||||
Mechanism of action | Sodium bicarbonate is a systemic alkalizer, which increases plasma bicarbonate, buffers excess hydrogen ion concentration, and raises blood pH, thereby reversing the clinical manifestations of acidosis. It is also a urinary alkalizer, increasing the excretion of free bicarbonate ions in the urine, thus effectively raising the urinary pH. By maintaining an alkaline urine, the actual dissolution of uric acid stones may be accomplished. Sodium bicarbonate acts as an antacid and reacts chemically to neutralize or buffer existing quantities of stomach acid but has no direct effect on its output. This action results in increased pH value of stomach contents, thus providing relief of hyperacidity symptoms. [PharmGKB] | ||||||||||||||||||||||||
Absorption | Not Available | ||||||||||||||||||||||||
Protein binding | Not Available | ||||||||||||||||||||||||
Biotransformation | Not Available | ||||||||||||||||||||||||
Route of elimination | Not Available | ||||||||||||||||||||||||
Toxicity | Not Available | ||||||||||||||||||||||||
Affected organisms |
|
||||||||||||||||||||||||
Interactions | |||||||||||||||||||||||||
Drug Interactions |
|
||||||||||||||||||||||||
Food Interactions | Not Available |
Hydrogen ions | |
---|---|
Name | Hydrogen ions |
Gene Name | Not Available |
Pharmacological action | yes |
Actions | neutralizer |
References |
|
DTHybrid score | Not Available |
Electrogenic sodium bicarbonate cotransporter 1 | |
---|---|
Name | Electrogenic sodium bicarbonate cotransporter 1 |
Gene Name | SLC4A4 |
Actions | substrate |
References |
|
DTHybrid score | Not Available |
Sodium bicarbonate cotransporter 3 | |
Name | Sodium bicarbonate cotransporter 3 |
Gene Name | SLC4A7 |
Actions | substrate |
References |
|
DTHybrid score | Not Available |
Electroneutral sodium bicarbonate exchanger 1 | |
Name | Electroneutral sodium bicarbonate exchanger 1 |
Gene Name | SLC4A8 |
Actions | substrate |
References |
|
DTHybrid score | Not Available |
Electrogenic sodium bicarbonate cotransporter 4 | |
Name | Electrogenic sodium bicarbonate cotransporter 4 |
Gene Name | SLC4A5 |
Actions | substrate |
References |
|
DTHybrid score | Not Available |
Sodium-driven chloride bicarbonate exchanger | |
Name | Sodium-driven chloride bicarbonate exchanger |
Gene Name | SLC4A10 |
Actions | substrate |
References |
|
DTHybrid score | Not Available |
Id | Partner name | Gene Name | Score |
---|